UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Iden ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q3 2020 Earnings Conference Call October 29, 2020 4:30 PM ET Company Participants David Carey - IR, Lazar Partners Ltd. Jack Peurach - President & Chief Executive Officer Bill Shaw - Chief Commercial Officer Jack Glenn - Chief Financial Officer Conference Call Participants RK Ramakanth - H.C. Wainwright Operator Greetings, and welcome to Ekso Bionics Third Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A bri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Start Time: 16:30 January 1, 0000 5:00 PM ET Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q2 2020 Earnings Conference Call July 30, 2020, 16:30 PM ET Company Participants Jack Peurach - President and CEO Jack Glenn - CFO Bill Shaw - Chief Commercial Officer David Carey - IR, Lazar Partners Ltd. Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Nathan Weinstein - Aegis Capital Operator Greetings, and welcome to Ekso Bionics Second Quarter 2020 Financial Results Call. At this time, all partic ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q1 2020 Results Earnings Conference Call April 30, 2020 4:30 PM ET Company Participants David Carey - Investor Relations, Lazar Partners Ltd. Jack Peurach - President and Chief Executive Officer Bill Shaw - Chief Commercial Officer Jack Glenn - Chief Financial Officer Conference Call Participants Sean Lee - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corp. Operator Greetings and welcome to the Ekso Bionics First Quarter 2020 Financial Results Conference C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q ____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1 ...

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2019 Earnings Conference Call February 27, 2020 4:30 PM ET Company Participants Matt Steinberg - Lazar Partners Jack Peurach - President, CEO & Director William Shaw - Chief Commercial Officer John Glenn - CFO & Secretary Conference Call Participants Dennis Pak - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corporation Operator Greetings and welcome to the Ekso Bionics Fourth Quarter 2019 Financial Results Conf ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value EKSO Nasdaq Stock Market LLC (Nasdaq Capital Market) WASHINGTON, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37854 Ekso Bionics H ...

Ekso Bionics Holdings Inc (NASDAQ:EKSO) Q3 2019 Results Conference Call October 30, 2019 4:30 PM ET Company Participants David Carey - Investor Relations Jack Peurach - President and Chief Executive Officer Jack Glenn - Chief Financial Officer Bill Shaw - Chief Commercial Officer Conference Call Participants Craig Bijou - Cantor Fitzgerald Swayampakula Ramakanth - HC Wainwright Nathan Weinstein - Aegis Capital Corp Operator Greetings and welcome to Ekso Bionics Third Quarter 2019 Financial Results Conferenc ...